Pharmaceutical and Biotechnology Market Report Catalog - August 2012

Market Report Catalog Pharmaceutical/Biotechnology
August 2012
Global Information, Inc.

Japan Head Office USA Office Europe Office Singapore Office Korea Office Taiwan Office Tel: 81-44-952-0102 Tel: 1-860-674-8796 Tel: 32-2-535-7543 Tel: 65-6223-2436 Tel: 82-2-2025-2992 Tel: 886-2-2729-4219 Fax: 81- 44-952-0109 Fax: 1-860-674-8341 Fax: 32-2-403-1201 Fax: 65-6223-2735 Fax: 82-2-2025-2993 Fax: 886-2-2729-2018 E-mail: jp-info@gii.co.jp E-mail:us-info@gii.co.jp E-mail: eu-info@gii.co.jp E-mail: sg-info@gii.co.jp E-mail: koreainfo@gii.co.jp Email: tw-info@gii.co.jp
http://www.giiresearch.com/
August 2012
Pharmaceutical/Biotechnology
Table of Contents
United States Market for Ankylosing Spondylitis Pharmacotherapy ...........................................................................................1 United States Market for Rheumatoid Arthritis Pharmacotherapeutics.......................................................................................1 Analysis of the Therapeutic Monoclonal Antibodies Market in Europe.......................................................................................2 Single Cell Technologies Trends 2012 .........................................................................................................................................2 Strategic Analysis of the Clinical Research Organization Market in India..................................................................................3 Global Markets for Stem Cells.....................................................................................................................................................3 Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019 ...........................................................4 Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 ....................................................................5 U.S. Market for Orthopedic Soft Tissue Repair and Sports Medicine 2012.................................................................................6 Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing ......................................................................................................................................................7 Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2012..................................................................8 Congenital Heart Disease Global Clinical Trials Review, H1, 2012 ...........................................................................................9 Open-Angle Glaucoma Global Clinical Trials Review, H1, 2012................................................................................................9 Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2012 ....................................................10 Chronic Pain Global Clinical Trials Review, H1, 2012 .............................................................................................................10 Ulcers Global Clinical Trials Review, H1, 2012........................................................................................................................11 Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2012 ........................................................................11 End-stage Renal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2019..................................................12 Nonmelanomatous Skin Cancer Global Clinical Trials Review, H1, 2012 ................................................................................13 Kinase Inhibitors: Global Markets -- Focus on Europe.............................................................................................................13 Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019 ...............................................................14 Atopic Dermatitis (Eczema) Global Clinical Trials Review, H1, 2012 ......................................................................................15 Pregnancy Global Clinical Trials Review, H1, 2012 .................................................................................................................15 Kinase Inhibitors: Global Markets -- Focus on the U.S. ...........................................................................................................16 General Anxiety Disorder Global Clinical Trials Review, H1, 2012..........................................................................................16 Other Metabolic Disorders Global Clinical Trials Review, H1, 2012 .......................................................................................17 Kinase Inhibitors: Global Markets -- Focus on Emerging Markets...........................................................................................17 Kinase Inhibitors: Global Markets -- Focus on Asia .................................................................................................................18 Analysis of the U.S. Cancer Biomarker Testing Market.............................................................................................................18 China Blood Products Industry Report, 2011-2012 ...................................................................................................................19 United States Market for Psoriatic Arthritis Pharmacotherapy.................................................................................................19 Medical Information Teams and Call Center Management .......................................................................................................20 Global Markets for Membrane Technology for Pharmaceuticals ..............................................................................................20 Healthcare Landscape, Outlook, and Growth Opportunities in Brazil ......................................................................................21 Kinase Inhibitors: Global Markets ............................................................................................................................................21 Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles..................................................................................................................................22 Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits...................23 Best Practices: The Evolving Commercial Genomics IT Landscape .........................................................................................24 Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production ..................................................................................................25 Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth......................................................................................................................................26 Gene Therapy Market to 2018 - Product Development Slowed by Clinical Failures, Close Regulatory Surveillance and High Compliance Standards ...............................................................................................................................................................27 Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue ............................................................................................................................................28 Global Markets for Enzyme Inhibitors -- Focus on the US........................................................................................................29 World Wound Care Markets (Skin Ulcer, Burns, Surgical/Trauma) ...........................................................................................29 Breast Cancer Diagnostic and Drug Technologies: Global Markets.........................................................................................30 Global Markets for Enzyme Inhibitors -- Focus on Europe .......................................................................................................30 Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets .....................................................................................31 ELISA Assay Trends 2012 ..........................................................................................................................................................31 2012 US Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications ..32 2012 European Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications by Country ...................................................................................................................................................32 2012 UK Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications .33 2012 Spain Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications33
August 2012
2012 Italy Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/ Applications...............................................................................................................................................................................34 2012 France Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications ......................................................................................................................................................................34 2012 Japan Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/ Applications...............................................................................................................................................................................35 2012 World Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications by Country .................................................................................................................................................................................36 2012 Germany Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications ......................................................................................................................................................................37 Deglutition Disorders Global Clinical Trials Review, H1, 2012................................................................................................37 Japan Sexually-Transmitted Diseases: Market Outlook and Emerging Opportunities ..............................................................38 Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2012 ..........................................................38 Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019..................................................39 Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019.............................40 Healthcare, Regulatory and Reimbursement Landscape Vietnam .............................................................................................41 Varicose Veins Global Clinical Trials Review, H1, 2012 ...........................................................................................................41 Sedation Global Clinical Trials Review, H1, 2012 ....................................................................................................................42 Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 .................42 Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 ..........................43 Strabismus Global Clinical Trials Review, H1, 2012.................................................................................................................43 Reperfusion Injury Global Clinical Trials Review, H1, 2012.....................................................................................................44 Ischemia Global Clinical Trials Review, H1, 2012 ....................................................................................................................44 Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019........................................................................45 Liver Failure Global Clinical Trials Review, H1, 2012 .............................................................................................................45 Infectious Immunology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018 ............................46 Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019.....................................................47 Venous Leg Ulcers Global Clinical Trials Review, H1, 2012.....................................................................................................48 Sjogren's Syndrome Global Clinical Trials Review, H1, 2012 ...................................................................................................48 Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019.............................................................49 Hepatitis A Global Clinical Trials Review, H1, 2012.................................................................................................................50 Sexually-Transmitted Diseases (STD): Global Market Outlook and Emerging Opportunities ..................................................51 Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017................................................................................................................................................................................52 Healthcare, Regulatory and Reimbursement Landscape Russia................................................................................................53 US Sexually-Transmitted Diseases: Market Outlook and Emerging Opportunities...................................................................53 2012 UK Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares .............................................54 2012 Strategic Analysis of the Global Coagulation Testing Market: Forecasts and Supplier Shares by Country .....................55 2012 Germany Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares ....................................56 2012 France Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares .......................................56 2012 Spain Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares..........................................57 2012 Japan Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares .........................................58 Research Report on China's Antihypertensive Medicine Market, 2012 .....................................................................................59 2012 Italy Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares............................................60 2012 US Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares ..............................................61 Drug Discovery Technologies....................................................................................................................................................61 Genitourinary Drugs: Technologies and Global Markets..........................................................................................................62 Mesenchymal Stem Cells - Advances & Applications ................................................................................................................63 Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications........................................................................................................................................................64 Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar ........................................................................65 Partnering Agreements with Bigpharma 2012...........................................................................................................................66 Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures ..............................................................................................................................................................................67 Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process.................................................................................................................68 Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth ...............................69 Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward .....................................................................................................................................................................................70 Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making.......................................................................................................................................................................................71 European Contrast Media and Radiopharmaceuticals Market..................................................................................................72 Consumer Health: Trends, Developments and Prospects ..........................................................................................................72 Healthcare, Regulatory and Reimbursement Landscape - Philippines......................................................................................73 Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019 .................................................................................73
ii
August 2012
Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019.......74 Global Markets for Enzyme Inhibitors.......................................................................................................................................74 Ariad Pharmaceuticals: PharmaVitae Report ...........................................................................................................................75 The Market for Mobile Medical Apps ........................................................................................................................................76 Vaccine Partnering Terms and Agreements................................................................................................................................77 What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) .......................................................................................................................................................................78 Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies............................................................79 Product Strategies for Non-Oral Hematology Drugs.................................................................................................................80 Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products ...........................................81 Epigenetic Screening Trends 2012 .............................................................................................................................................81 Product Profiles: Asthma - Key companies act to maintain dominance ....................................................................................82 China Animal Vaccine Industry Report, 2011-2012 ...................................................................................................................82 Research Report on China's Blood Product Industry, 2012.......................................................................................................83 Chinese Markets for Pharmaceutical Packaging.......................................................................................................................84 Life Sciences & Analytical Reagents Market - Applications, Current Trends, Opportunities & Global Forecasts (2011 - 2016) .............................................................................................................................................................................85 Global Flow Cytometry Market .................................................................................................................................................86 The New Generation of Antibody Therapeutics: Current Status and Future Prospects .............................................................86 DNA Sequencing and PCR Markets...........................................................................................................................................87 Transdermal Hormone Replacement: Products, Players, Markets and Forecasts.....................................................................87 Ear Care - Country Reports.......................................................................................................................................................88 Systemic Nasal Sprays: Products, Players, Markets and Forecasts ..........................................................................................89 Wound Care - Country Reports..................................................................................................................................................89 Weight Management - Country Reports.....................................................................................................................................90 Nrt Smoking Cessation Aids - Country Reports .........................................................................................................................90 Medicated Skin Care - Country Reports ....................................................................................................................................91 Herbal/Traditional Products - Country Reports ........................................................................................................................91 Eye Care - Country Reports.......................................................................................................................................................92 Oral Transmucosal Drug Delivery: Products, Players, Markets & Forecasts...........................................................................92
iii
August 2012
Pub. Date 2012/07/05
United States Market for Ankylosing Spondylitis Pharmacotherapy

Price Please contact us for pricing Published by Frost & Sullivan This research service covers the United States market for ankylosing spondylitis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this research is on biologics and other treatments prescribed as add-on therapies; background standard of care therapies are not covered in this study. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors and non-TNF biologics. Table of Contents 1. Ankylosing Spondylitis Pharmacotherapeutics Market 2. Ankylosing Spondylitis Pharmacotherapeutics Market - Total Ankylosing Spondylitis Pharmacotherapeutics Market 3. TNF Inhibitor Segment 4. Non-TNF Biologics Segment 5. The Last Word 6. Appendix
http://www.giiresearch.com/ce/246428
Pub. Date 2012/07/05
United States Market for Rheumatoid Arthritis Pharmacotherapeutics

Price Please contact us for pricing Published by Frost & Sullivan This research service covers the United States rheumatoid arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed used on top of background standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment paradigms for rheumatoid arthritis and patient flow dynamics through lines of therapy are also included. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics, and novel oral disease-modifying antirheumatic drugs (DMARDs). Table of Contents Rheumatoid Arthritis Pharmacotherapeutics Market
Research Service Executive Summary Total Rheumatoid Arthritis Pharmacotherapeutics Market External Challenges: Drivers and Restraints United States Market for Rheumatoid Arthritis Pharmacotherapeutics - Analysis by Market Segment The Last Word Three Big Predictions Appendix
August 2012
Pub. Date 2012/07/05
Analysis of the Therapeutic Monoclonal Antibodies Market in Europe

Price Please contact us for pricing Published by Frost & Sullivan The research service aims to analyse and assess the Therapeutic Monoclonal Antibodies market in Europe. This is performed by analysing the key trends and dynamics shaping the industry sector in correlation with the market drivers and restraints. With several key blockbuster drugs losing patent protection and an immense rise in the rate of disease incidences, the use of monoclonal antibodies for therapeutics has been on the increase. The tendency towards biologics has been on the increase during the past decade. This research service provides an in-depth knowledge of the key European markets by presenting significant growth opportunities for the existing drugs and those in the pipeline until 2016. Table of Contents 1. Executive Summary 2. Market Overview 3. External Challenges: Drivers and Restraints Monoclonal Antibodies Market 4. Forecasts and Trends Monoclonal Antibodies Market 5. Market Share and Competitive Analysis: Monoclonal Antibodies Market 6. Segmentation by Therapeutics 7. Regional Analysis of the Monoclonal Antibodies Market 8. The Last Word 9. Appendix
Pub. Date 2012/07/03
Single Cell Technologies Trends 2012

Price USD 2500 PDF by E-mail (Company License) Published by HTStec Ltd
HTStec's Single Cell Technologies 2012 report was published on 3 July 2012. This 58 page report summarizes the results of HTStec's industry-wide global web-based benchmarking survey on single cell technologies carried out in June 2012. The questionnaire was compiled to meet the needs, requirements and interests of our clients, who were manufacturers/developers of laboratory equipment for separation, sorting and analysis of single cells. They wish to gain insight into the application requirements, market opportunities, unmet needs and demand for single cell technology-related products. The report is based on 202 responses, from persons or groups currently using or planning future use of single cells or single cell enabling technologies in their research efforts. Respondents were segmented on the basis of their current field of interest and use of single cell technologies with 57% undertaking basic research; 36% applied research and 7% pharma research.
August 2012
Pub. Date 2012/07/03
Strategic Analysis of the Clinical Research Organization Market in India

Price Please contact us for pricing Published by Frost & Sullivan This research deliverable provides detailed insights into the clinical development and outsourcing market of India. It also includes an overview of the Indian regulatory and R&D process briefing. It describes the Clinical trials scenario today at a therapeutic level of focus. Furthermore, it highlights the key trends, drivers, restraints and also the challenges faced by the clinical research market today. The research deliverable also covers the forecast of the CRO market from 2010 to 2016. The research service also gives a deeper insight, not only into the phase-wise, but also therapy-wise details of the clinical trials. An understanding of increasing R&D expenditures by different pharmaceutical companies is also given. Table of Contents 1. Executive Summary 2. Indian Regulatory and R&D Environment Overview 3. India Clinical Trials Scenario 4. Indian CRO: Market Analysis 5. Indian CRO Market Demand Slide Analysis (Pharma and Biotech Companies) 6. Conclusion and Recommendations 7. About Frost & Sullivan
Pub. Date 2012/07/02
Global Markets for Stem Cells

Price USD 4850 PDF by E-mail (Single User License) USD 5950 PDF by E-mail (Business Unit License) USD 8500 PDF by E-mail (Enterprise License) Published by BCC Research
The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription drug products. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the stem cell-related drug market. The wider economic environment is also taken into account. The report examines strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market. REASONS FOR DOING THE STUDY Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced a number of significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.
August 2012
Pub. Date 2012/07/02
Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Price USD 3995 PDF by E-mail (Single user license) USD 7990 PDF by E-mail (Site license) USD 11985 PDF by E-mail (Global license) Published by GlobalData
GlobalData, the industry analysis specialist, has released its new report, "Diabetic Foot Ulcer Therapeutics Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Foot Ulcers Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope The report provides information on the key drivers and challenges of the Diabetic Foot Ulcers Therapeutics market. Its scope includes
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Foot Ulcers Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries Diabetic Foot Ulcers Therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Diabetic Foot Ulcers Therapeutics market. Analysis of key recent licensing and partnership agreements in Diabetic Foot Ulcers Therapeutics market
August 2012
Pub. Date 2012/07/02
Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, "Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Toxoplasmosis Therapeutics market. The report identifies the key trends shaping and driving the global Toxoplasmosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Toxoplasmosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope The report provides information on the key drivers and challenges of the Toxoplasmosis Therapeutics market. Its scope includes
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Toxoplasmosis Therapeutics
market revenues data from 2006 to 2011, forecast for eight years to 2019.
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and
emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries Toxoplasmosis Therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Toxoplasmosis Therapeutics market. Analysis of key recent licensing and partnership agreements in Toxoplasmosis Therapeutics market
August 2012
Pub. Date 2012/07/01
U.S. Market for Orthopedic Soft Tissue Repair and Sports Medicine 2012
Price USD 6995 Hard Copy USD 7495 PDF by E-mail (Single User License) USD 8995 PDF by E-mail (Corporate License) The orthopedic soft tissue repair and sports medicine market consists of: Published by iData Research Inc.
anterior and posterior cruciate ligament (ACL/PCL) reconstruction fixation products meniscal repair devices cartilage repair therapies shoulder and labrum repair devices and hip arthroscopy devices
The hip arthroscopy market experienced the highest growth in 2010, as more surgeons are learning to perform these procedures. All market segments were affected by the economic downturn in 2008 and procedure numbers waned in 2009 and 2010. As the economy began recovering in the last quarter of 2010, residual demand boosted procedure volumes. Within the soft tissue and sports medicine market, companies such as Arthrex, ArthroCare, ConMed Linvatec, DePuy Mitek and Smith & Nephew lead the market, among many others. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2017, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
August 2012
Pub. Date 2012/07/01
Emerging Pharmaceutical Market in Brazil - Regulatory Framework Forces MNCs to Partner with Local Players Resulting in Profit and Control Sharing
Price USD 3500 PDF by E-mail (Single user license) USD 7000 PDF by E-mail (Site license) USD 10500 PDF by E-mail (Global license) Published by GBI Research
Brazil has a population of around 190 million, representing a gigantic audience for the pharmaceutical industry. The country is beginning to build a reputation for its high-quality clinical trials and biodiversity, and consequently Brazil is attracting foreign pharma giants, yet also looks to support local companies. Continuous support from the government is helping the Brazilian pharmaceutical market to grow at a compound annual growth rate (CAGR) of 9%, and to make its own mark on the global industry. The National Health Surveillance Agency (ANVISA), under the patronage of the Ministry of Health, is the main regulatory authority in Brazil. According to ANVISA's RDC 59/00 regulation, foreign firms looking to export to Brazil must submit an inspection request through representatives or registered importers, in order to certify products. This represents a significant obstacle to smaller foreign drug makers wishing to enter the Brazilian market, and has led to partnering agreements between multinational pharmaceutical firms with local players in Brazil. Pharmaceutical giants are also required to pay the local subsidiaries for product development and distribution, while the profits earned are shared between the two. This skillfully supports local companies, both financially and within the industry, as Brazilian pharmaceutical brands are given the opportunity to work alongside experienced players in the market. Prominent examples of investments by global pharmaceutical players include Sanofi's acquisition of Medley Pharmaceuticals and GlaxoSmithKline's co-development deal with Oswaldo Cruz Foundation. Brazil demands that foreign corporations actively participate with local companies to create a multinational and co-operative market, in which Brazil's benefits are still appealing to foreign companies and the local economy is also supported.
August 2012
Pub. Date 2012/06/30
Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, " Global Clinical Trials Review, H1, 2012" provides data on the Pre-Diabetes/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pre-Diabetes/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pre-Diabetes/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope
Data on the number of clinical trials conducted in North America, South and Central America, Europe,
Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued trials (suspended, withdrawn and terminated)
August 2012
Pub. Date 2012/06/30
Congenital Heart Disease Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Congenital Heart Disease Global Clinical Trials Review, H1, 2012" provides data on the Congenital Heart Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Congenital Heart Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Congenital Heart Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/30
Open-Angle Glaucoma Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Open-Angle Glaucoma Global Clinical Trials Review, H1, 2012" provides data on the Open-Angle Glaucoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Open-Angle Glaucoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Open-Angle Glaucoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
August 2012
Pub. Date 2012/06/30
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2012
GlobalData's clinical trial report, "Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2012" provides data on the Acute Renal Failure (ARF) (Acute Kidney Injury)/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Renal Failure (ARF) (Acute Kidney Injury)/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Renal Failure (ARF) (Acute Kidney Injury)/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/30
Chronic Pain Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Chronic Pain Global Clinical Trials Review, H1, 2012" provides data on the Chronic Pain/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Pain/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Pain/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
10
August 2012
Pub. Date 2012/06/30
Ulcers Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Ulcers Global Clinical Trials Review, H1, 2012" provides data on the Ulcers/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ulcers/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ulcers/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/30
Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2012" provides data on the Cytomegalovirus (HHV-5) Infections/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cytomegalovirus (HHV-5) Infections/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cytomegalovirus (HHV-5) Infections/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
11
August 2012
Pub. Date 2012/06/30
End-stage Renal Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "End-stage Renal Disease Therapeutics Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global End Stage Renal Disease Therapeutics market. The report identifies the key trends shaping and driving the global End Stage Renal Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global End Stage Renal Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope The report provides information on the key drivers and challenges of the End Stage Renal Disease Therapeutics market. Its scope includes
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) End Stage Renal Disease
Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries End Stage Renal Disease Therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the End Stage Renal Disease Therapeutics market. Analysis of key recent licensing and partnership agreements in End Stage Renal Disease Therapeutics market
12
August 2012
Pub. Date 2012/06/30
Nonmelanomatous Skin Cancer Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Nonmelanomatous Skin Cancer Global Clinical Trials Review, H1, 2012" provides data on the Nonmelanomatous Skin Cancer/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nonmelanomatous Skin Cancer/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nonmelanomatous Skin Cancer/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope
Pub. Date 2012/06/30
Kinase Inhibitors: Global Markets -- Focus on Europe

BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for kinase inhibitors. The key objective is to present a comprehensive analysis and the future direction of kinase inhibitors to provide an important tool for the usage of these types of enzyme inhibitors. This report explores present and future strategies within the kinase inhibitors market, which includes tyrosine inhibitors, multi-target kinase inhibitors, serine/ threonine inhibitors and monoclonal antibody kinase inhibitors. The direction of the market, its setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of enzyme inhibitors are also examined in the report. A detailed analysis of the kinase inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year period from 2011 through 2016. Applications for kinase inhibitors are also discussed separately in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and a summary of patents awarded in each category.
13
August 2012
Pub. Date 2012/06/30
Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, "Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Phenylketonuria Therapeutics market. The report identifies the key trends shaping and driving the global Phenylketonuria Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Phenylketonuria Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope The report provides information on the key drivers and challenges of the Phenylketonuria Therapeutics market. Its scope includes
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Phenylketonuria Therapeutics
market revenues data from 2006 to 2011, forecast for eight years to 2019.
emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries Phenylketonuria Therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Phenylketonuria Therapeutics market. Analysis of key recent licensing and partnership agreements in Phenylketonuria Therapeutics market
14
August 2012
Pub. Date 2012/06/30
Atopic Dermatitis (Eczema) Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Atopic Dermatitis (Eczema) Global Clinical Trials Review, H1, 2012" provides data on the Atopic Dermatitis (Eczema) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Atopic Dermatitis (Eczema). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Atopic Dermatitis (Eczema). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/30
Pregnancy Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Pregnancy Global Clinical Trials Review, H1, 2012" provides data on the Pregnancy/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pregnancy/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pregnancy/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
15
August 2012
Pub. Date 2012/06/30
Kinase Inhibitors: Global Markets -- Focus on the U.S.

Pub. Date 2012/06/30
General Anxiety Disorder Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "General Anxiety Disorder Global Clinical Trials Review, H1, 2012" provides data on the General Anxiety Disorder/Impaired Glucose Toleranceclinical trial scenario. This report provides elemental information and data relating to the clinical trials on General Anxiety Disorder/Impaired Glucose Tolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating General Anxiety Disorder/Impaired Glucose Tolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
16
August 2012
Pub. Date 2012/06/30
Other Metabolic Disorders Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Other Metabolic Disorders Global Clinical Trials Review, H1, 2012" provides data on the Other Metabolic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Other Metabolic Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Other Metabolic Disorders. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/30
Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

Price USD 3900 PDF by E-mail (Single User License) USD 4785 PDF by E-mail (Business License) USD 6835 PDF by E-mail (Enterprise License) Published by BCC Research
17
August 2012
Pub. Date 2012/06/30
Kinase Inhibitors: Global Markets -- Focus on Asia

Pub. Date 2012/06/29
Analysis of the U.S. Cancer Biomarker Testing Market

Price USD 6000 Web Access (Regional License) USD 6500 Web Access (Regional License) & Hard Copy Published by Frost & Sullivan
This research service analyzes the U.S. cancer biomarker testing market from 2009 to 2017. Topics include an overview of the market, along with definitions, metrics, drivers, and restraints. Also offered is an evaluation of ongoing technology trends and major market competitors and their corresponding market shares and product offerings. Based on this analysis, revenue forecasts and growth rates are projected for each segment of the market. This study also provides cancer epidemiology trends, voice-of-customer research on oncologists, and the challenges and strategies for cancer biomarker validation. Table of Contents 1. U.S. Cancer Biomarker Testing Market Research Service Total U.S. Cancer Biomarker Testing Segment Molecular Cancer Biomarker Testing Segment Breakdown Traditional Cancer Biomarker Testing Segment Breakdown The Last Word Appendix
18
August 2012
Pub. Date 2012/06/29
China Blood Products Industry Report, 2011-2012

Price USD 2300 PDF by E-mail (Single User License) USD 2400 Hard Copy USD 3600 PDF by E-mail (Enterprise-wide License) Published by ResearchInChina
Recent years have seen fast-growing development of blood product industry in China, with the enterprises concerned numbering 33 which can produce 10-odd blood products including human albumin, human immunoglobulin (pH4) for intravenous injection and human immunoglobulin. In 2003-2010, the CAGR of blood products reached 20.3% in China, far above the global level in the same period. Thanks to many favorable factors such as the advance of economy and technology, the acceleration of population growth and aging process as well as the people' s further recognition of blood products, China' s blood product market has seen buoyant momentum which is expected to maintain until 2015 and beyond. However, the blood products of China have always seen short supply due to limited blood plasma source. Especially, since August 2011 when 16 plasma collection stations were closed in GuizhouProvince, the production of China-based blood product enterprises has been further constrained.
Pub. Date 2012/06/29
United States Market for Psoriatic Arthritis Pharmacotherapy

This research service covers the United States psoriatic arthritis pharmaceuticals market from 2009 to 2017, with 2011 as the base year. The focus of this study is prescription therapeutics prescribed and used as well as the background standard of care. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: tumor necrosis factor (TNF) inhibitors, non-TNF biologics and novel oral disease-modifying antirheumatic drugs (DMARDs). Table of Contents 1. Psoriatic Arthritis Pharmacotherapeutics Market Research Service Psoriatic Arthritis Pharmacotherapeutics Market United States Market for Psoriatic Arthritis Pharmacotherapeutics: Analysis by Market Segment The Last Word Appendix
19
August 2012
Pub. Date 2012/06/27
Medical Information Teams and Call Center Management

Price USD 7695 PDF by E-mail (Single User License) Published by Cutting Edge Information
Sales forces and MSLs may interact with physicians, but medical information teams and call centers answer tens of thousands of inquiries each year. This team acts as an essential point of contact for audiences that vary from medical professionals to patients - not to mention internal clients and stakeholders. While effective medical information teams embrace patient-centric attitudes, these teams must also work to increase their visibility within the pharmaceutical company. Medical information is a valuable resource for colleagues who know how to leverage the team's expertise. This team acts as a repository for all product information and reference clinical data, positioning them to support not only field forces, but also market access and medical affairs teams. Of all medical information team responsibilities, call center management remains the most important and costly. These teams must work to ensure that call centers represent the company in the best way. Call centers must be outfitted with the best standard response documents, effective technology, and adequate staffing and budget so that they can evolve to meet the needs of today's changing client base.
Pub. Date 2012/06/27
Global Markets for Membrane Technology for Pharmaceuticals

Membrane technology is used in all phases of the pharmaceutical development processes, from laboratory research to large-scale pharmaceutical manufacturing. Applications include lab-scale DNA and protein separation and analysis, sample preparation, drug screening, cell culturing and examination, laboratory and process water purification, virus removal, and bench-, pilot-, and production-scale drug manufacturing. Substantial changes in the pharmaceutical and biopharmaceutical industries have made membrane separations processes an important part of the production of drugs. Membrane separation processes help ensure safety and efficacy of drugs by eliminating contaminants from the laboratory through large-scale production. This study is an update of a previous report from 2005; it combines bio-pharmaceutical, life science research, and pharmaceutical membrane separation technologies.
20
August 2012
Pub. Date 2012/06/27
Healthcare Landscape, Outlook, and Growth Opportunities in Brazil

This research service analyzes the Brazilian healthcare system through the revenue of pharmaceutical and biotechnology drugs, medical devices, medical equipment, clinical diagnostics, and administrative clinical healthcare IT systems. It also delivers an overview of the Brazilian Unified Health System (the SUS) as well as an overview of Brazil's healthcare infrastructure with a breakdown by region and type. The research service also examines the country's private insurance plans, its demographics, and its disease burdens. Industry challenges, drivers, and restraints that are anticipated to impact the Brazilian healthcare market are given for the forecast period, which ends in 2015. Consequent growth opportunities are also analyzed. Table of Contents
Executive Summary Market Overview Demographics and Disease Burden Total Healthcare Market Pharmaceuticals and Biotechnology Segment Breakdown Medical Devices Segment Breakdown Healthcare IT Segment Breakdown Medical Imaging Segment Breakdown Clinical Diagnostics Segment Breakdown The Last Word The Frost & Sullivan Story
Pub. Date 2012/06/26
Kinase Inhibitors: Global Markets

21
August 2012
Pub. Date 2012/06/25
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
Standardized Clinical Trials Endpoints to Help Health Authorities Tackle Respiratory Diseases. We all know that smoking and some allergies are bad for our lungs, but now science is standardizing the way that we measure respiratory health, helping to judge the effectiveness of drug treatments better than ever, according to a new report by healthcare experts GBI Research. The new report* shows that asthma and chronic obstructive pulmonary disorder (COPD), common conditions causing breathing difficulties, are now being studied using a set of common clinical endpoints, which help to standardize test results and draw conclusions regarding the effectiveness of new drugs. COPD is cited as the fourth most common cause of death in the US by the National Institute of Health, representing a collection of progressive lung diseases including emphysema and chronic bronchitis, often caused by smoking, and is proving a heavy economic burden for state healthcare. Therefore, is has been imperative for health authorities to further improve on their endpoint measurements in order to compare the available treatment options for these disorders. Clinical trial endpoints are used to measure the outcomes of medical testing, assessing the effects of new treatments. Endpoints in respiratory disease clinical trials should be accurate, precise, easily measurable and reliable, and range from techniques such as daily symptoms scoring, use of rescue medication and the quality of life score, to more specific vital signs such as measuring pulmonary function, respiratory rate and pulse. The endpoints used in respiratory clinical trials are often chosen depending on the developmental stage of the molecule being studied, as agencies require Phase III trials to study direct clinical endpoints in order to grant drug approvals. Physicians confirm diagnoses of asthma using pulmonary function tests (PFT), and classify the condition based on Peak Expiratory Flow (PEF) rate, frequency of symptoms and Forced Expiratory Volume (FEV). It is therefore not surprising that FEV was used in 29.9% of completed Phase III clinical trials for asthma products as a primary endpoint during 2000-2010, while another 29.3% of these trials used multiple PFT as a secondary endpoint.
22
August 2012
Pub. Date 2012/06/25
Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits
Pharma Supply Chains under the Microscope: Raising Revenue and Cutting out Counterfeiters. The pharmaceutical companies are paying more attention than ever before to their supply chains as they attempt to boost profits and clamp down on fake drugs, states a new report by healthcare industry analysts GBI Research. The report* examines the growing importance of strategic supply chain management in maximising revenue for global pharmaceutical companies, and how this is prompting the revision of traditional business models. International pharmaceutical corporations are starting to tailor supply chains to products based on market demand and production costs. While manufacturing is commonly out-sourced to emerging economies where labor expenses are less substantial, branded products are produced closer to customer bases in developed countries as profit margins are higher and transportation costs lower. These companies are also employing third-party logistics firms to improve flexibility in times of fluctuating demand. When drug requirements drop, pharmaceutical firms can simply reduce the order volume, rather than rendering costly in-house facilities inoperative. GBI Research's latest report also explains how developments in transportation methods are combating counterfeit drugs in the pharmaceutical industry - primarily through the implementation of Radio-Frequency Identification (RFID). In the US, product callbacks have increased steadily over the last decade, with the Food and Drug Administration (FDA) recalling 1,742 drugs in 2009 alone. This occurs for a number of reasons including poor quality packaging, defective labelling and contamination. As RFID devices are embedded in product packs and scanned by special readers, they eliminate human error as well as the need to replace labelling damaged in transit. But perhaps the most prominent quality of this technology is the capacity to store comprehensive and encrypted data, therefore reducing the possibility of fake medications entering the supply chain. Traditionally, counterfeit drugs are manufactured in huge quantities and enter the system with bogus batch numbers and product codes that are identical to legitimate originals. Once in the supply chain these fakes are very difficult to recall, resulting in unnecessary expense for the firm and damaging public opinion. RFID is an important weapon in tackling this problem.
23
August 2012
Pub. Date 2012/06/25
Best Practices: The Evolving Commercial Genomics IT Landscape

Price USD 4500 PDF by E-mail (Single user license) Published by IDC Health Insights
This IDC Health Insights report highlights the impending arrival of the $1,000 genome and its likely impact on transforming the life science industry forever. With a detailed view of leading trends as well as the current leading technology, IT, and informatics innovators supporting progress in this increasingly important space, we hope to provide readers with a snapshot of where we are and the likely players that will help drive future progress from both a general IT and an industry-specific vendor perspective. While much remains left to be learned, we are clearly on a path forward that should enable improved patient outcomes from a more personalized medicine-based future. "While genomics may eventually be found to have only a supporting role in the manifestation of many human diseases, the advent of the age of genomics will still transform the life science and healthcare industries by accelerating progress in our understanding of human biology at the molecular level," says Alan S. Louie, research director, IDC Health Insights.
24
August 2012
Pub. Date 2012/06/25
Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
The global market for biosimilar drugs is due to come under attack from popular generic drugs, as governments fight to control rising healthcare expenditure, according to healthcare experts GBI Research. The new report* states that governments in emerging economies are struggling to match the soaring demand for cheaper drugs, due to an increase in disease prevalence stemming from population growth, old age and unhealthy lifestyles. However, the increasing awareness of biosimilars among physicians and patients could help biosimilars to gain significant market share, leading companies to consider offering reimbursements to patients for biosimilar products. Clinical activities for biosimilars can take six to eight years - a time-consuming and costly process - and, while generic drug manufacturing can cost up to $5m, biosimilar development can cost as much as $80m-$120m. This is primarily due to the complex structure of biological drugs, which are difficult to manufacture, and the high number of patients required for trials to prove efficacy and safety. The possibility of failure in the biosimilars development process is also significant, and even obtaining marketing authorization for biosimilars is an extensive and difficult process. As a result, only a small number of companies can afford to enter the biosimilars market. Patients can save around 30% through buying biosimilars rather than the corresponding innovator products, but this is still comparatively more expensive than generic drugs, which can offer up to a 90% saving. Given that a biologic treatment for metastatic cancer can cost as much as $200,000 per year, even a substantial reduction in the cost of treatment with biosimilars will not match the value of generics. Most patients in emerging economies pay for medicine-related costs out-of-pocket, and affordability is therefore an issue for biosimilar manufacturers. The biosimilars market in emerging economies was valued at $0.3 billion in 2002 and grew to a value of $3.3 billion in 2010 at a Compound Annual Growth Rate (CAGR) of 34%. It is forecast to grow further at a CAGR of 12% from 2010 to 2018, reaching $8 billion by 2018 at a CAGR of 12%.
25
August 2012
Pub. Date 2012/06/25
Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
Generics are predicted to take over the antiviral drugs market, especially in the case of HIV medication, as a series of patent expiries will open opportunities for ambitious companies to seize huge revenue, according to a new report by healthcare experts GBI Research. The new report* states that an increase in the patient population and reforms in government policies will work together to encourage the rise of generic pharmaceutical powers. Government policies include the need for prior authorization in order to dispense branded drugs that have generic alternatives, while further incentives are available from Pharmacy Benefit Managers (PBM) for dispensing generic drugs. These kinds of regulatory changes and financial benefits could act as significant drivers of the market during the forecast period. While it is estimated that, in 2010, generics accounted for 18.9% of the market share in the global antivirals market, this market share is forecast to grow to reach 29.2% by 2018. This is largely due to a series of patent expiries expected to hit the antiviral market, which will act to raise the value of generic antiviral drugs to over $9 billion by 2018. Generics in the HIV market in particular accounted for an estimated majority market share of 46% in the total generic antivirals market during 2010. HIV generics are expected to create a boom in the market, due to a loss of patent exclusivity for key antiviral drugs. The generic market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. However, many major patent expiries are expected during the forecast period, including Sustiva (efavirenz) and Kaletra (lopinavir + ritonavir) in 2013, Prezista (darunavir ethanolate) in 2014, and major Nucleoside Reverse Transcriptase Inhibitors (NRTIs) such as Trizivir (abacavir sulphate/lamivudine/zidovudine), Epzicom (lamivudine and abacavir) and Emtriva (emtricitabine) in 2016. By 2018, billions of dollars' worth of industry revenue will be lost from the expiry of these brand name products, and the race will be on for generics manufacturers to create new superstar drugs to make the most of this unmet need in the market. Generics within the antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018. In December 2011, Teva launched generic Combivir in the US market as a combination tablet containing lamivudine and zidovudine, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Combivir had annual sales of approximately $556m in 2010, based on the annual report.
26
August 2012
Pub. Date 2012/06/25
Gene Therapy Market to 2018 - Product Development Slowed by Clinical Failures, Close Regulatory Surveillance and High Compliance Standards
Price USD 3500 PDF by E-mail (Single user license) USD 7000 PDF by E-mail (Site license) USD 10500 PDF by E-mail (Global license) Gene Therapy: the Next Big Step in Cancer Treatments. The fight against cancer is leading a new movement in gene therapy, as the failure of conventional cancer therapies is fuelling demand for new treatments, according to a new report by healthcare experts GBI Research. The new report* states that gene therapy technology is still in its nascent stage, and high levels of regulatory surveillance in clinical development is affecting progress. However, the increasing potential of upcoming treatments and shortcomings in traditional therapies is gradually leading to broader acceptance of gene therapy in medicine. Therapies such as chemotherapy and hormone therapy control the progression of diseases, but are often associated with severe side effects, such as nausea, hair loss and abnormal blood cell counts. Once administered, the drugs induce systemic action throughout the body, and patients often die due to the side effects of treatment rather than the cancer itself. The inability of these conventional therapies to cure diseases has created a significant unmet need in the treatment of cancer, as well as Human Immunodeficiency Virus (HIV), autoimmune diseases, and viral infections. Targeted therapies such as monoclonal antibodies, stem cell therapies, Ribonucliec Acid (RNA) therapies and gene therapies have initially shown better efficacy and safety profiles compared to chemotherapies. Gene therapy has several promising drug candidates, which are likely to drive the growth of the gene therapy market if clinical trials are successful. Collategene by AnGes MG, Cardium Therapeutics' Generx, and Vical Incorporation's Allovectin-7 are in development for a wide range of cancer indications, and are expected to compete in the oncology therapeutics market as the market acceptance of gene therapy improves over time. Published by GBI Research
27
August 2012
Pub. Date 2012/06/25
Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue
Argentina is boosting the health of their citizens thanks to strong government schemes that are providing medical attention to those that need it, while financially supporting the country's in house pharmaceutical production, according to a new report from healthcare experts GBI Research. The new report shows that the Argentine pharmaceutical market is expected to witness significant growth in the near future, based on predicted increases in government healthcare spending, which are set to support the country's citizens by providing comprehensive medical care. While 15 % of total government expenditure was spent on healthcare in 2009, a higher ratio than that of most emerging countries, schemes such as the Remediar program, which runs a network distributing essential drugs directly to local clinics in low-income neighborhoods and is funded by the government and the Ministry of Health (MOH), are set to further increase expenditure in coming years. Argentina's pharmaceutical market is one of the fastest-growing markets in Latin America, having blossomed since the country's economic crisis of 2001-2002. Amidst the financial turmoil, large domestic companies acquired the divested manufacturing facilities of multinational pharmaceutical companies and established themselves in the market to support the country's healthcare needs. The Argentine pharmaceutical market is therefore now dominated by local pharmaceutical companies, which accounted for 58% of the industry's revenue in 2010. Pharmaceuticals produced by domestic laboratories within the country accounted for around 94% of the revenue, with only the remaining 6% of drug sales relying on foreign imports.
28
August 2012
Pub. Date 2012/06/22
Global Markets for Enzyme Inhibitors -- Focus on the US

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors. This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report. A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016. Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.
Pub. Date 2012/06/22
World Wound Care Markets (Skin Ulcer, Burns, Surgical/Trauma)

Price USD 3995 PDF by E-mail (Single User License) USD 5995 PDF by E-mail (Departmental License) USD 7990 PDF by E-mail (Global Site License) Published by Kalorama Information
The wound care industry is a highly diverse and competitive arena - including standard products such as dry bandages bandages to sophisticated hydrogels and alginate dressings, and encompassing artificial skin and anti-infectives used in wound care. The aging population and more prevalent conditions such as diabetes are driving wound care, and these trends are all influenced by future demographic trends, economic uncertainty, the impact of health care reform, increasing numbers of uninsured patients, reimbursement pressures from third party payers, continuing shortage of nurses and physicians and increasing technology and supply costs. Emerging wound care products and technologies are well-positioned to capitalize on the growth in patient numbers and the demand from healthcare systems to reduce hospital stays. It' s important for wound care makers to know the areas where their products will be utilized most.
29
August 2012
Pub. Date 2012/06/22
Breast Cancer Diagnostic and Drug Technologies: Global Markets

This BCC market research report provides a detailed overview and thorough analysis of the present and future global market for breast cancer diagnostics and drug technologies. It provides detailed analysis of the breast cancer drug and diagnostics markets, as well as the currently used personalized, predictive and companion tests and their markets. The research also includes market characterization, opportunities, the unmet needs associated with breast cancer, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition and the key players of the breast cancer market. This report includes products in this market and detailed analyses of markets and competitive environments. It also analyzes current and future market prospects. It provides a comprehensive review of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to companion tests, tumor markers and gene profiling assays relevant for breast cancer prognosis and diagnosis. The analysis reviews technological developments, product innovations and recent strategic industry activity of major players across different product categories. It analyzes their strengths and weaknesses, opportunities and threats facing various devices and drugs in this market space and developments already on the market. It discusses the major issues involved in the research and development (R&D) of more effective devices for drug delivery to the lungs, along with new products in development.
Pub. Date 2012/06/22
Global Markets for Enzyme Inhibitors -- Focus on Europe

30
August 2012
Pub. Date 2012/06/22
Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets

Pub. Date 2012/06/20
ELISA Assay Trends 2012

HTStec's ELISA Assay Trends 2012 report was published on 20 June 2010. This 56 page report summarizes the results of HTStec' s 2nd industry-wide global web-based benchmarking survey on enzyme-linked immunosorbent assays (ELISA) carried out in June 2012. The main objectives were to comprehensively document current practices and preferences in ELISA assays, and to understand future user requirements. It also examines interest in adopting new or emerging ELISA platforms with potential to significantly improve performance. The report is based on 93 responses, from a range of organisation types (ELISA end-users) from across the globe. Respondents were segmented on the basis of their ELISA activity with 47% undertaking applied research; 29% routine testing and 24% basic research.
31
August 2012
Pub. Date 2012/06/19
2012 US Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
Price USD 8400 PDF by E-mail (Local license) USD 18500 PDF by E-mail (Global license) Published by Venture Planning Group
This report presents a comprehensive analysis of the US molecular diagnostics market, including:
Major issues pertaining to the US molecular diagnostics laboratory practice, as well as key economic, regulatory,
demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Ten-year test volume and reagent sales forecasts for the following categories: Review of testing methodologies an instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns.
Pub. Date 2012/06/19
2012 European Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications by Country
This comprehensive five-country report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years. The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
32
August 2012
Pub. Date 2012/06/19
2012 UK Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
This report presents a comprehensive analysis of the UK molecular diagnostics market, including:
Major issues pertaining to the UK molecular diagnostics laboratory practice, as well as key economic, regulatory,
demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Ten-year test volume and reagent sales forecasts for the following categories: Review of testing methodologies an instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns.
Pub. Date 2012/06/19
2012 Spain Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
This report presents a comprehensive analysis of the Spanish molecular diagnostics market, including:
Major issues pertaining to the Spanish molecular diagnostics laboratory practice, as well as key economic,
regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Ten-year test volume and reagent sales forecasts for the following categories: Review of testing methodologies an instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns.
33
August 2012
Pub. Date 2012/06/19
2012 Italy Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
This report presents a comprehensive analysis of the Italian molecular diagnostics market, including:
Major issues pertaining to the Italian molecular diagnostics laboratory practice, as well as key economic,
regulatory, demographic, social and technological trends with significant market impact during the next ten years.
An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in
testing automation and amplification methods.
Ten-year test volume and reagent sales forecasts for the following categories Review of testing methodologies an instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing
tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns.
Pub. Date 2012/06/19
2012 France Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
This report presents a comprehensive analysis of the French molecular diagnostics market, including:
Major issues pertaining to the French molecular diagnostics laboratory practice, as well as key economic,
Ten-year test volume and reagent sales forecasts for the following categories: Infectious Diseases Review of testing methodologies an instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing
Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns.
34
August 2012
Pub. Date 2012/06/19
2012 Japan Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
This report presents a comprehensive analysis of the Japanese molecular diagnostics market, including:
Major issues pertaining to the Japanese molecular diagnostics laboratory practice, as well as key economic,
Ten-year test volume and reagent sales forecasts for the following categories: Review of testing methodologies
an instrumentation technologies.
Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing
Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns
35
August 2012
Pub. Date 2012/06/19
2012 World Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications by Country
This comprehensive seven-country, 1,050-page report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the NAT market during this decade. Highlights
Business and technological trends in seven major markets Five- and ten-year test volume and sales forecasts Market shares of leading competitors Feature comparison of major analyzers Profiles of market players and start-up firms developing innovative technologies and products Specific product and business opportunities for instrument and consumable suppliers.
Rationale The NAT market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next ten years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the NAT market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next ten years.
36
August 2012
Pub. Date 2012/06/19
2012 Germany Molecular Diagnostics Market Strategic Analysis: Supplier Shares and Sales Forecasts for 35 Tests/Applications
This report presents a comprehensive analysis of the German molecular diagnostics market, including:
Major issues pertaining to the German molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods. Ten-year test volume and reagent sales forecasts for the following categories: Review of testing methodologies an instrumentation technologies. Feature comparison of automated and semiautomated analyzers. Sales and market shares of leading suppliers. Over 60 specific opportunities for molecular diagnostic instruments, test systems, IT and auxiliary products. Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies. Alternative market penetration strategies. Potential market entry barriers and risks. Business planning issues and concerns.
Pub. Date 2012/06/18
Deglutition Disorders Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Deglutition Disorders Global Clinical Trials Review, H1, 2012" provides data on the Deglutition Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Deglutition Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Deglutition Disorders. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
37
August 2012
Pub. Date 2012/06/18
Japan Sexually-Transmitted Diseases: Market Outlook and Emerging Opportunities

This report presents detailed analysis of the Japanese STD market, including sales forecasts and supplier shares for Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), and Syphilis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report:
Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other
emerging technologies;
Reviews features and operating characteristics of major analyzers used for STD testing; Profiles key suppliers and potential market entrants developing innovative technologies and products; and Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and
strategic planning issues.
Pub. Date 2012/06/18
Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2012
GlobalData's clinical trial report, "Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2012" provides data on the Peripheral Neuropathy (Sensory Neuropathy) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peripheral Neuropathy (Sensory Neuropathy). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peripheral Neuropathy (Sensory Neuropathy). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
38
August 2012
Pub. Date 2012/06/18
Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Osteoarthritis (OA) Pain Therapeutics Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Osteoarthritis Pain Therapeutics market. The report identifies the key trends shaping and driving the global Osteoarthritis Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Osteoarthritis Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
39
August 2012
Pub. Date 2012/06/18
Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope The report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Its scope includes -
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic Stress Disorder
(PTSD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019. Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD) Therapeutics market
40
August 2012
Pub. Date 2012/06/18
Healthcare, Regulatory and Reimbursement Landscape Vietnam

GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Vietnam". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape of Vietnam. It identifies the key trends in the healthcare market of Vietnam and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the country. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts. The population of Vietnam was approximately 86.5 million in 2010, making it the 13th most populated country in the world. This increase in the population is primarily due to a high birth rate and an increase in life expectancy. An increasing disease burden is a matter of concern for policy planners in Vietnam. The pharmaceutical market in the country was $1.9 billion in 2010 and is expected to reach approximately $5.8 billion by 2020 at a projected CAGR of 12%. The positive trend in the healthcare market of Vietnam can be primarily attributed to -
Increasing coverage of public health insurance in the country High expenditure on healthcare Government initiatives for the prevention and management of chronic diseases An improved and updated regulatory environment
Pub. Date 2012/06/18
Varicose Veins Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Varicose Veins Global Clinical Trials Review, H1, 2012" provides data on the Varicose Veins clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Varicose Veins. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Varicose Veins. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
41
August 2012
Pub. Date 2012/06/18
Sedation Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Reperfusion Injury Global Clinical Trials Review, H1, 2012" provides data on the Reperfusion Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Reperfusion Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Reperfusion Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/18
Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. The report identifies the key trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
42
August 2012
Pub. Date 2012/06/18
Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report identifies the key trends shaping and driving the global Gastrointestinal Stromal Tumors (GIST) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gastrointestinal Stromal Tumors (GIST) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Pub. Date 2012/06/18
Strabismus Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Strabismus Global Clinical Trials Review, H1, 2012" provides data on the Strabismus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Strabismus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Strabismus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope
43
August 2012
Pub. Date 2012/06/18
Reperfusion Injury Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Reperfusion Injury Global Clinical Trials Review, H1, 2012" provides data on the Reperfusion Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Reperfusion Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Reperfusion Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/18
Ischemia Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Ischemia Global Clinical Trials Review, H1, 2012" provides data on the Ischemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ischemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ischemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
44
August 2012
Pub. Date 2012/06/18
Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, "Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Acute Pain Therapeutics market. The report identifies the key trends shaping and driving the global Acute Pain Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Acute Pain Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Pub. Date 2012/06/18
Liver Failure Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Liver Failure Global Clinical Trials Review, H1, 2012" provides data on the Liver Failure clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Failure. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Failure. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
45
August 2012
Pub. Date 2012/06/18
Infectious Immunology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
GlobalData's new report, "Infectious Immunology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018" provides key data, information and analysis on the global infectious immunology market. The report provides market landscape, competitive landscape and market trends information on the infectious immunology market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India,
Brazil and Australia.
Key segments covered include Hepatitis Viruses, Retroviruses, Bacteriology and Other Virology. Annualized market revenues data from 2004 to 2011 and forecast forward for seven years to 2018. Company
shares data for 2011.
Qualitative analysis of key market trends, market drivers, and restraints within infectious immunology market. The report also covers information on the leading market players, the competitive landscape, and the leading
pipeline products and technologies.
Key players covered include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthcare, Qiagen and
Gen-Probe Incorporated.
46
August 2012
Pub. Date 2012/06/18
Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Traumatic Brain Injury Therapeutics Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Traumatic Brain Injury Therapeutics market. The report identifies the key trends shaping and driving the global Traumatic Brain Injury Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Traumatic Brain Injury Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts Scope The report provides information on the key drivers and challenges of the Traumatic Brain Injury Therapeutics market. Its scope includes -
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Traumatic Brain Injury
Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries Traumatic Brain Injury Therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Traumatic Brain Injury Therapeutics market. Analysis of key recent licensing and partnership agreements in Traumatic Brain Injury Therapeutics market
47
August 2012
Pub. Date 2012/06/18
Venous Leg Ulcers Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Venous Leg Ulcers Global Clinical Trials Review, H1, 2012" provides data on the Venous Leg Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Leg Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Venous Leg Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
Pub. Date 2012/06/18
Sjogren's Syndrome Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Sjogren's Syndrome Global Clinical Trials Review, H1, 2012" provides data on the Sjogren's Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sjogren's Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sjogren's Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
48
August 2012
Pub. Date 2012/06/18
Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, "Hepatitis A Preventive Vaccines Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope The report provides information on the key drivers and challenges of the Hepatitis A Preventive Vaccines market. Its scope includes -
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hepatitis A Preventive Vaccines
market revenues data from 2006 to 2011, forecast for eight years to 2019. Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. Analysis of the current and future competition in the seven key countries Hepatitis A Preventive Vaccines market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hepatitis A Preventive Vaccines market. Analysis of key recent licensing and partnership agreements in Hepatitis A Preventive Vaccines market
49
August 2012
Pub. Date 2012/06/18
Hepatitis A Global Clinical Trials Review, H1, 2012

GlobalData's clinical trial report, "Hepatitis A Global Clinical Trials Review, H1, 2012" provides data on the Hepatitis A clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis A. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts. Scope
50
August 2012
Pub. Date 2012/06/18
Sexually-Transmitted Diseases (STD): Global Market Outlook and Emerging Opportunities

This report presents detailed analysis of the STD market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on epidemiology and etiology are presented for Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), and Syphilis. The report provides test volume and sales forecasts by country and market segment, including:
Hospitals Commercial/Private Labs Physician Offices Public Health Labs

In addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of STD diagnostic products, by test and country. Also, the report:
51
August 2012
Pub. Date 2012/06/18
Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017
Price USD 4395 PDF by E-mail (Single User License) USD 7395 PDF by E-mail (Multi User License) USD 10395 PDF by E-mail (Corporate License) Published by Transparency Market Research
This report analyzes the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) for the period 2010 to 2017. The major product segments in this market consist of bronchodilators, anti-inflammatories, and combination therapies. The report also describes the key influencing factors for the global asthma and COPD market. Market analysis and forecasts are provided for the period 2010 through 2017. Definition, estimates & forecast of the global asthma and COPD market from 2010 to 2017
Analysis of sub-segments for asthma and COPD market Analysis of the latest trends in the industry Acumen into the size and shape of the market growth
This research is specially designed to estimate and analyze the demand and performance of the global asthma and COPD market. The report covers all the major segments of asthma and COPD market and provides in-depth analysis, market revenue, and trend analysis by segments and statistically refined forecast for the segments covered. The in-depth research and high level analysis will allow asthma and COPD product manufacturers, service providers, marketing companies, research and development agencies to make informed decisions about asthma and COPD manufacturing, marketing, growth strategies and how best to gain competitive advantage.
52
August 2012
Pub. Date 2012/06/18
Healthcare, Regulatory and Reimbursement Landscape Russia

GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Russia". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical devices markets. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts. Russia's population decreased at a CAGR of 0.1% between 2005 and 2010. As in most developed countries, the population contains a high proportion of elderly people, with approximately 13.2% of the population above the age of 65 years in 2010. The disease burden associated with this large elderly population is expected to boost growth in the pharmaceutical market, although hinder growth in the economy at the same time. Russia's pharmaceutical market is one of the fastest growing markets in the world, and was valued at approximately $18.7 billion in 2010, having grown at a CAGR of 23% from 2005. The medical device market is one of the most stable industries in the healthcare sector. The main segments in 2010 were diagnostic imaging, ophthalmic devices, cardiovascular devices, in vitro diagnostics and diabetes care devices.
Pub. Date 2012/06/18
US Sexually-Transmitted Diseases: Market Outlook and Emerging Opportunities

This report presents detailed analysis of the US STD market, including sales forecasts and supplier shares for Chancroid, Chlamydia, Gonorrhea, Herpes (I/II, VI), Papillomavirus (Pap Smear, HPV), and Syphilis. The report provides test volume and sales projections for Hospitals, Commercial, Physician Offices, and Public Health Labs. In addition to market share and sales forecasts, the report:
53
August 2012
Pub. Date 2012/06/15
2012 UK Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the UK coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
54
August 2012
Pub. Date 2012/06/15
2012 Strategic Analysis of the Global Coagulation Testing Market: Forecasts and Supplier Shares by Country
This comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the global coagulation testing market during this decade. Available by country and section. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
55
August 2012
Pub. Date 2012/06/15
2012 Germany Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the German coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
Pub. Date 2012/06/15
2012 France Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the French coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
56
August 2012
Pub. Date 2012/06/15
2012 Spain Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the Spanish coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
57
August 2012
Pub. Date 2012/06/15
2012 Japan Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the Japanese coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
58
August 2012
Pub. Date 2012/06/15
Research Report on China's Antihypertensive Medicine Market, 2012

Price USD 2800 Hard Copy USD 2800 PDF by E-mail (Single user license) USD 4200 PDF by E-mail (Enterprisewide license) Published by China Research and Intelligence
In recent years, with Chinese people's living standards continuously improving and elderly people increasing, prevalence rate of hypertension incessantly rises. Presently, there's still no effective means to cure hypertension. According to the WHO statistics about death of various diseases, death toll of cardiovascular disease which is represented by hypertension increases from 28.8% of the total mortality toll in 1997 to 36.0% in 2002. Hypertension is a serious danger to human health. According to a press release issued by the International Society of Hypertension, the number of global hypertension or abnormally high blood pressure crowds reaches 972 million, accounting for 26.4% of the world's adult population. With the invention and application of CCB, ACEI, ARB and other new-generation antihypertensive medicines, the mortality rate of various cardiovascular diseases sharply declines. Nevertheless, there are still 17 million people across the world die from cardiovascular and cerebrovascular diseases caused by hypertension and half of them die from acute myocardial infarction and cerebrovascular embolism. So people pay high attention to antihypertensive medicine market. Hypertension is defined referring to the large-scale epidemiological survey result. China respectively developed different diagnostic criteria and stages for four times in 1959, 1974, 1979 and 1999 aligning with different national conditions. In October 1999, by referring to the WHO/ISH hypertension treatment guidelines, the Chinese Hypertension League defined hypertension as SBP 140mmhg and (or) DBP 90mmhg without taking antihypertensive medicine and according to blood pressure levels, hypertension is divided into grades 1, 2, 3 which nearly matches light, moderate and severe levels used in the past. Revising diagnostic criteria for four times reflect that China cardiovascular physicians constantly deepen the awareness of hypertension prevention and control and advance with the time. Recently, along with the release of JNC-7 and European hypertension prevention and control guidelines and the closure of some large-scale clinical trials, China will develop new hypertension prevention and treatment guidelines in accordance with national conditions.
59
August 2012
Pub. Date 2012/06/15
2012 Italy Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the Italian coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
60
August 2012
Pub. Date 2012/06/15
2012 US Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares
This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate growth opportunities and strategies emerging in the US coagulation testing market during this decade. The report explores business and technological trends; provides estimates of the test volume for 35 assays, as well as sales and market shares of leading reagent and instrument suppliers; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers. Rationale The growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in molecular diagnostics, chromagenic substrates, monoclonal antibodies, immunoassays, IT and laboratory automation will radically change coagulation testing practice. Specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating POC opportunities and challenges for suppliers.
Pub. Date 2012/06/14
Drug Discovery Technologies

This market research report, Drug Discovery Technologies, provides an overview of the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches. The study includes information about significant players in this field of study, trends and obstacles, and other information affecting development of new products, devices, and therapies in the drug discovery sector. REASONS FOR DOING THIS STUDY Drug discovery is one of the main sectors in the pharmaceutical industry. Drug development in general is a billion dollar industry and is highly dependent on its research and scientific advancement. Today, the process of drug discovery has become more systematic in comparison to the more physiological approaches in previous decades. In the current drug discovery market, the drug target is identified first, followed by a search for compounds or molecular entities that can inhibit or enhance its activity. Consequently, technology has a crucial impact on identification and validation of new drug candidates.
61
August 2012
Pub. Date 2012/06/14
Genitourinary Drugs: Technologies and Global Markets

This study provides a comprehensive analysis of the market for genitourinary drugs on a global basis. Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends, in order to quantify and qualify the market for drug products to treat various genitourinary diseases in both men and women. Individual drug product-types are forecast on a global basis, as are overall disease segments. Forecasts and trends are developed from a cross-reference of data points, gleaned from proprietary industry sources, company publications, industry benchmarking, and other divergent data sources to arrive at a cogent and coordinated forecast. REASONS FOR DOING THE STUDY For companies with an effective strategy, market opportunity awaits. Importantly, the ability to develop an effective strategy begins with where opportunity exists and ends with how to effectively execute the strategy to capture profit from opportunity. The genitourinary disease drug market presents a significant part of the overall pharmaceutical product market worldwide. This study investigates the specific classes of genitourinary diseases and the pharmaceutical products for their treatment. Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed. Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period. This report analyzes emerging markets by disease category. Continued growth is expected in emerging geographies, driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.
62
August 2012
Pub. Date 2012/06/13
Mesenchymal Stem Cells - Advances & Applications

Price USD 3995 PDF by E-mail (Single User License) USD 3995 Hard Copy (Single User License) USD 4995 PDF by E-mail (Site License) USD 5995 PDF by E-mail (Global License) Published by BIOINFORMANT WORLDWIDE, LLC
Overview: Analysis of global grant activity, scientific publication rates, and patent applications reveal that research activity involving mesenchymal stem cells increased 58% year-over-year from 2008 to 2009, and 112% from 2009 to 2010. Of most interest is that this rate of growth accelerated in 2011, making mesenchymal stem cells the fastest growing area of stem cell research. Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells. MSCs are of intense therapeutic interest because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for several reasons. First, they avoid the ethical issues that surround embryonic stem cell research. Second, repeated studies have found that human MSCs are immuno-privileged, and therefore, represent an advantageous cell type for allogenic transplantation, reducing the risks of rejection and complications of transplantation. Recently, there have also been significant advances in the use of autologous MSCs to regenerate human tissues, including cartilage and meniscus, tendons, and bone fractures. This market research report focuses on recent advances in MSC research applications, explores research priorities by market segment, highlights individual labs and end-users of MSC research products, explores the competitive environment for MSC research products, and provides 5-year growth and trend analysis. The report advantageously positions companies that wish to offer competitive stem cells products to this rapidly growing, well-funded research community.
63
August 2012
Pub. Date 2012/06/12
Translational Regenerative Medicine - Oncology, CNS and Cardiovascular-Rich Pipeline Features Innovative Stem Cell and Gene Therapy Applications
Standardized research guidelines are needed to control and encourage the development of gene therapy and stem cell treatments, according to a new report by healthcare experts GBI Research. The new report* shows how regenerative medicine is seen as an area with high future potential, as countries need ways to cope with the burden of an aging population. The stem cell market alone is predicted to grow to around $5.1 billion by 2014, while gene therapy has also shown promise despite poor understanding of some areas of regenerative medicine and a lack of major approvals (the only approvals to date being made in Asia). Up until now, securing research within clinics has been difficult, with a high number of failures and discontinuations throughout all phases of clinical study. Stem cell therapy uses bone marrow transplants as an established treatment method, but the development of the therapy into further applications and has not yet become common practice. Similarly, tissue engineering has been successful in the areas of skin and bone grafts, but translation into more complex therapies has been an issue for researchers. Although scientific possibilities are ever-increasing, the true potential of regenerative medicine has yet to be demonstrated fully. A desire to discover new and innovative technologies has encouraged governments in the UK and Singapore to focus directly on regenerative medicine as a future potential economy booster. They have provided funding and incentives for companies to conduct their research in the country, along with the creation of hubs of knowledge and permissive regulatory environments to encourage research. Funding for industry and research groups is a vital part of furthering regenerative medicine, especially in taking therapies through clinical trials and on to commercialization. As more regions find a desire to attract industry and expertise, more focus is likely to be given to regenerative medicine.
64
August 2012
Pub. Date 2012/06/12
Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
The osteoporosis therapeutics market is the primary reason for the continued growth of the global bone metabolism sector, according to a report from specialists in healthcare analysis, GBI Research. The new report* shows that the osteoporosis treatment sector accounted for 68% of worldwide bone metabolism revenue for 2010 - far out outweighing the other components of the market, Paget's disease of bone, hyperparathyroidism and bone metastases. The strong performance of the osteoporosis market is expected to continue, with GBI Research predicting it will help the overall bone metabolism therapeutics market reach a value of $27.1 billion by 2018. Due to a strong pipeline, however, the bone metastases market is expected to contribute more significantly in the coming years. GBI Research's report indicates that while the bone metastases treatments available at the moment are adequate, there are gaps in for these potentially impressive options. There are currently 47 molecules in various stages of clinical development for bone metastases and many of these are First-In-Class. Xeva is expected to make a big impact in the European market following market authorisation, whereas late stage pipeline molecule, Xgeva, has been approved and is currently making an impression in the US and Japan. Molecules Alpharadin and Orazol, both expected to hit in 2014, also look very promising.
65
August 2012
Pub. Date 2012/06/12
Partnering Agreements with Bigpharma 2012

Price Published by Current Partnering, a division of Wildwood Ventures Limited USD 2695 PDF by E-mail (Single User License) The Partnering Agreements with Bigpharma 2012 report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. This premier report provides all the information you require to better understand bigpharma partnering. One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions. Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years. This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities.
66
August 2012
Pub. Date 2012/06/12
Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures
China's expectations of growth in the national pharmaceutical industry could prove a major hurdle in the country's race for universal healthcare by 2020, according to a new report by healthcare industry analysts GBI Research. The report* states that the key factor in cultivating these two potentially conflicting projects may rest on the careful balancing of drug prices. China's Essential Drug System (EDS), which includes the National Essential Drug List (NEDL), forms the spine of the country's healthcare system and is responsible for providing drugs at affordable prices in government hospitals. Mandated price cuts over the last few years have had the combined effect of stemming healthcare expenditure while improving access to medications for the poor and uninsured. The National Development and Reform Commission (NDRC) introduced a 17% price cut to 174 drugs in December 2010, and a 21% cut to 162 drugs in March 2011, with the NDRC stating the latter series of reductions will bring about an annual saving of RMB 10 billion ($1.5 billion). However, drug sales are used to subsidise public hospitals and funding is required to spur on China's pharmaceutical industry, so finding the right balance may prove to be biggest challenge in the creation of a universal healthcare system. The NDRC also plans to cut the prices of other medicines, the initial prices of which are determined by the government. These prices are based on production cost and the condition of market supply and demand. It is expected that the Chinese government will gradually narrow the price premium of the same drugs, between multinational and domestic manufacturers.
67
August 2012
Pub. Date 2012/06/12
Emerging Pharmaceutical Market in South Africa to 2017 - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
The South African pharmaceutical market is expected to almost double in the next six years due to profitable government contracts for HIV/AIDS and tuberculosis medications, according to the latest report from market analysts GBI Research. The new report* predicts that the South African pharmaceutical industry will grow from a value of $3.8 billion in 2011 to $7 billion in 2018, climbing at a Compound Annual Growth Rate (CAGR) of 9.2%. Though it was once dismissed as low-profit, the country's pharmaceutical industry is now regarded as having great potential and is attracting the attention of some of the sector's big players. To tackle South Africa's crippling problem with HIV/AIDS and TB, the government is awarding tenders that promise steady returns for two to three years to companies offering appropriate treatments. The African nation has the highest proportion of people with HIV/AIDS in the world. According to figures from 2010, over five million residents have the virus and around 40% of deaths in that year were related to HIV/AIDS. To aid the fight against the epidemic, the government receives international support from organisations such as the Global Fund, the President's Emergency Plan For AIDS Relief (PEPFAR) and the EU. The national government is also in the process of introducing a new regulatory body with the goal of speeding up the drug registration process. The South African Health Products Regulatory Authority (SAHPRA) will replace the current healthcare body, the Medicines Control Council (MCC), in a transition that is hoped to be complete within the year.
68
August 2012
Pub. Date 2012/06/12
Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth
Biologics industry growth in the BRIC countries (Brazil, Russia, India and China) is expected to outpace traditional markets, according to a new report by business intelligence providers GBI Research. The report* states that, until recently, these emerging markets did not figure in the plans of the major pharmaceutical companies, but due to financial and political developments they are now seen as important countries in the pharmaceutical industry. In terms of growth, it is anticipated that the BRIC countries will outstrip traditional markets like Europe and the US, albeit from a lower revenue base, in the years to come. GBI Research reports these burgeoning economies are projected to account for over a quarter of the global biological market revenues by 2015. The biologic sector is increasingly important to the pharma industry due to stagnation in R&D productivity and concerns over the so-called "patent cliff", with an established first generation of biologic therapies representing 24 of the top selling pharmaceutical products worldwide. While the patent cliff has largely affected small-molecule synthetic drugs which have been the staple of pharmaceutical prosperity for decades, biologic treatments are emerging as a greater standard of care and are more difficult to replicate and manufacture. These therapies are biological rather than chemical developments that promise greater effectiveness due to their capacity to target the underlying cause of disease and form personalized medicines.
69
August 2012
Pub. Date 2012/06/12
Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward
Major pharmaceutical companies are being forced to change tact in order to prosper in a continuingly strained industry, finds a report by business intelligence specialists GBI Research. The new report* states that as the global economic crisis rolls on, swingeing cuts made in R&D and manufacturing by the pharmaceutical industry's big players is affecting the way the sector looks at future development. While these companies are addressing the issue of workforce reduction in different ways, a number of common tactics have emerged, including a greater focus on emerging markets, the outsourcing of activities regarding drug discovery and the building of closer links with academic institutions. Firms are supporting this new emphasis on external productivity by setting up incubators on company premises to support emerging new companies and supporting life science research through the development of innovation funds and venture capital groups. The financial decline that followed the huge expansion enjoyed by global pharmaceutical companies in the 1990s and early 2000s has resulted in significantly weakened R&D budgets and numerous site closures. Since 2009, the US has seen the closure of 18 R&D locations and the EU has seen the shutdown of 14. Notably, the UK has been particularly hard-hit with the closure of six sites, representing 19% of the worldwide total.
70
August 2012
Pub. Date 2012/06/12
Re-evaluating Pharmaceutical Pipelines - Emerging Markets, Biologics and Orphan Drugs to Shape Future Decision Making
Co-operation will be key to the development of pharmaceuticals in coming years in order to avoid further struggles caused by isolated paths of discovery within the biotech industry, according to a new report by pharmaceutical experts GBI Research. The new report* discusses how industry leaders have blamed the lack of improvements in pharma productivity on the industry's closed innovation systems, which rely primarily on utilizing in-house expertise to address the challenges faced by product research and development (R&D). However, during the last decade, the pharmaceutical sector has begun to embrace an open innovation R&D model, establishing cooperative alliances, partnerships and joint ventures with R&D specialists to make use of diverse expertise and technologies in order to help develop proactive solutions and expand their potential markets. In 2008, Czerepak and Ryser investigated the sources of drugs approved by the FDA as well as those failing in Phase III during the period January 2006 to December 2007, from small, medium and large pharmaceutical companies. Of the 103 FDA approvals, 46% were from biotech, 16% from pharma-biotech relationships, and 39% from pharmaceutical companies. Interestingly, only 30% of products were new chemical entities/novel drugs, while 30% were line extensions and 40% were "me-toos". According to the investigation, more than 50% of novel drug approvals were originally generated by the biotech industry, and 95% of the phase III failures were products originating from biotech companies. The pharmaceutical industry was therefore proven to have a much better success rate than biotech companies in getting drugs approved in the US during this investigation. However, 40% of all pharmaceutical companies' approved products were sourced from the biotech industry, either through collaborations or acquisitions.
71
August 2012
Pub. Date 2012/06/11
European Contrast Media and Radiopharmaceuticals Market

This research service aims to provide a detailed analysis of the contrast media and radiopharmaceuticals market in European nations, focusing on the United Kingdom, Germany, France, Italy, Spain, and Benelux and Scandinavian countries. This research service includes a brief market overview of contrast media and radiopharmaceuticals, the transport mechanisms for radiopharmaceuticals, analysis of the challenges affecting the industry, factors driving and restraining the growth of the market, and the revenue forecasts. The main objectives of this study are to provide an understanding of market opportunities, market size, and forecast assessment. Table of Contents 1. Executive Summary 2. Market Overview 3. External Challenges: Drivers and Restraints 4. Forecasts and Trends - Radiopharmaceuticals Market 5. Forecasts and Trends - Contrast Media Market 6. Regional Breakdown 7. Strategic Recommendations 8. Conclusion and Appendix
Pub. Date 2012/06/11
Consumer Health: Trends, Developments and Prospects

Price USD 2000 PDF by E-mail (Single user license) Published by Euromonitor International
Consumer health is flourishing under the influence of key demographic, regulatory, public health and corporate trends. Ageing populations offer a growing customer base, as does widespread urbanisation in developing markets. More regulatory oversight is spurring innovation and bolstering consumer confidence in self-care. Government and commercial wellness campaigns are also educating consumers. Companies are exploring regional and portfolio expansion, and are engaging consumers using technology. Euromonitor International's Consumer Health: Trends, Developments and Prospects global briefing examines the size, growth trends and potential opportunities in the Consumer Health market. The strategic analyses include assessing the impacts of changing regulations, research breakthroughs and public health concerns on both the market and leading companies. Consumer attitudes towards the products and their personal healthcare needs are also explored. Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management. Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.
72
August 2012
Pub. Date 2012/06/07
Healthcare, Regulatory and Reimbursement Landscape - Philippines

GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Philippines". The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of Philippines. The report identifies the key trends in the healthcare market of Philippines. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Philippines. Most importantly, the report provides valuable insights on the trends and segmentation of pharmaceutical market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts. The population of Philippines in 2010 was approximately 94 million and was the 12th most populated country in the world. The increase in the population is primarily due to high birth rate and increase in life expectancy. An increasing elderly population is a matter of concern for the policy planners of Philippines. The pharmaceutical market in Philippines was $3 billion in 2010 and is expected to reach approximately $7.4 billion by 2020 at a projected CAGR of 9.4%.
Pub. Date 2012/06/07
Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, the industry analysis specialist, has released its new report, "Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Gout Therapeutics market. The report identifies the key trends shaping and driving the global Gout Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Gout Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
73
August 2012
Pub. Date 2012/06/07
Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
GlobalData, the industry analysis specialist, has released its new report, "Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. The report identifies the key trends shaping and driving the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Pub. Date 2012/06/07
Global Markets for Enzyme Inhibitors

74
August 2012
Pub. Date 2012/06/06
Ariad Pharmaceuticals: PharmaVitae Report

Price USD 5700 PDF by E-mail (Single user license) Published by Datamonitor
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug. Features and benefits
Gain insight into Ariad Pharmaceuticals' strategic outlook Analyze company sales forecasts by product
Highlights Ariad's most advanced product candidate is ponatinib, which the company believes has potential in hematological cancers and solid tumors. It is in a pivotal Phase II trial and Ariad plans to file for marketing approval of ponatinib in the US and Europe in the third quarter of 2012. Ariad's second-closest product to approval is AP26112, an investigational dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). These are both targets in non-small cell lung cancer (NSCLC). Depending on the outcome of a Phase I/II trial, Ariad envisions starting a pivotal trial in NSCLC patients in 2013.
75
August 2012
Pub. Date 2012/06/06
The Market for Mobile Medical Apps

Use of mobile devices in the healthcare field has taken off in a way not surprising given the fast pace of healthcare work. Innovative companies have been well ahead of this trend and launched applications that are seeing revenues. Kalorama Information has studied the market over the past two years and found a growing market with room for new entrants. This Kalorama Information report, The Worldwide Market for Mobile Medical Apps detailsthe smartphone and other mobile applications or apps that are being utilized in many areas of healthcare: education, health management, data management, health information, and other workflow processes. and presents a picture of the market today and what it may look like over the next five years. The report provides revenue estimates and forecasts for apps by device used:
Apple Android Nokia Palm Windows Others and by application category: Nursing Tools Drug References Study Tools (includes games and flashcards) Medical Reference Clinical Support Systems
The total mobile medical app market is also broken out by region including US, Europe, Asia and Rest of World markets. The report discusses some popular apps that are being used in the clinical setting and business models that have worked for their creators.
76
August 2012
Pub. Date 2012/06/06
Vaccine Partnering Terms and Agreements

Price Published by Current Partnering, a division of Wildwood Ventures Limited USD 2695 PDF by E-mail (Single User License) The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 1,500 links to online copies of actual vaccine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
77
August 2012
Pub. Date 2012/06/05
What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines in the pipeline.This Kalorama Information report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched. What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? The following target areas are covered in the report:
Acne Addiction Allergy Alzheimer's Disease Anthrax Asthma Campylobacter Infection Chlamydia Croup Cytomegalovirus (CMV) Dengue Fever Diabetes Ebola Epstein-Barr Virus Enterotoxigenic Escherichia coli (ETEC) Heart Attack Helicobacter Pylori Hepatitis Herpesvirus Hookworm Hypertension HIV/AIDS
78
August 2012
Pub. Date 2012/06/04
Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies
GBI Research's new report, "Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies", provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in Indonesia and in the Philippines. The report analyzes the overall pharma market structure in these countries, provides competitive benchmarking for the leading companies, and analyzes the M&A and strategic partnerships that shape the Indonesian and Filipino pharmaceutical market. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The Indonesian pharmaceutical industry exhibited high growth after the government announced a plan to allow 100% foreign ownership of drug firms to increase overseas investment in the sector and thereby raise the volume and quality of local production. The Philippines' pharmaceutical industry on the other hand witnessed slow growth due to a drug pricing law implemented by the government. The Indonesian pharmaceutical industry has noticeably changed since the approval of the Universally Accessible Cheaper and Quality Medicines Act that includes the Maximum Drug Retail Price (MDRP) scheme. MDRP called for a 50% price reduction for more than 100 drugs. Indonesia and the Philippines recently joined the ranks of the top 20 most populated countries in the world, meaning they offer huge patient populations. There has been a rise in the incidence of chronic diseases like diabetes, obesity, and cardiovascular disease. Emerging markets such as Indonesia must address the population's rising demand for healthcare and significant unmet medical needs. The Philippines' CRO market is gaining attention globally due to its favorable regulatory environment and huge patient base offered by the country's large population. However, the Indonesian CRO market is not as favorable for drugs registration procedures, which currently take 300 days after submission to the Indonesian Food and Drug Monitoring Agency (BPOM). Indonesia and the Philippines currently account for a tiny share of the global CMO market but are set to capitalize on increasing outsourcing opportunities from western countries.
79
August 2012
Pub. Date 2012/06/04
Product Strategies for Non-Oral Hematology Drugs

Price USD 2850 PDF by E-mail (Single User License) USD 4500 PDF by E-mail (Site License) USD 6500 PDF by E-mail (Enterprise License) Published by Greystone Research Associates
Greystone Research Associates is pleased to announce the publication of a new market study. Product Strategies for Non-Oral Hematology Drugs is a comprehensive analysis of the technology, products and participants that comprise this segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, formulation specialists, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and strategic opportunities for non-oral hematology drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study. The Evolving Landscape for Therapeutic Hematology Drugs The administration of non-oral drugs for the treatment of blood disorders has evolved over the past ten years to include heparin analogs and recombinant proteins designed to treat chronic conditions that are life threatening and often debilitating illnesses. As the availability of drugs based on new APIs or molecular entities has grown, the product strategies in the marketplace have increased in specificity and sophistication. The chronic nature of many blood diseases and the growing trend toward patient self-administration for non-oral medications is requiring drug developers and product managers to refine their product strategy at the highest level, with formulation and device selection decisions being made prior to the clinical trial phase of development. The result has been greater reliance on concurrent product development processes and stronger partnerships between drug companies and device designers. Formulations that can extend the half-life of hematology drugs are also gaining traction, as developers strive to create drugs with lower dosing frequencies as a way to improve patient safety and compliance. These factors are combining to make hematology drug product strategies more complex and multi-faceted, and challenging managers to think and react well beyond traditional drug development models.
80
August 2012
Pub. Date 2012/06/01
Error-Proof Entry, Expert Positioning, and Exploding Growth in Embryonic Stem Cell Products
Price USD 3495 PDF by E-mail (Single User License) USD 3545 Hard Copy (Single User License) USD 4495 PDF by E-mail (Site License) USD 5495 PDF by E-mail (Global License) Published by BIOINFORMANT WORLDWIDE, LLC
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research. Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain. However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.
Pub. Date 2012/06/01
Epigenetic Screening Trends 2012

The survey was initiated by HTStec as part of its tracking of this emerging life science marketplace and to update HTStec's previous report (June 2010). The questionnaire was compiled to meet the needs, requirements and interests of the epigenetic vendor community. The objective was to comprehensively document current practices and preferences in epigenetic enzyme screening assays, to understand future user requirements, and interest in outsourcing. Equal emphasis was given to soliciting opinion from Pharma, Biotech and Academic Research market segments in both North America and Europe. The survey looked at the following aspects of epigenetic enzyme screening assays, as practiced today (2012) and in some cases as predicted for the future (2014): level of enthusiasm for epigenetic target biology; key diseases/therapeutic area(s) investigating epigenetic enzyme assays; epigenetic target classes/proteins of greatest interest, where assay feasibility has been investigated and primary screens run; main source/origin of epigenetic enzymes/proteins; where current commercial recombinant proteins are adequate; where improved biochemical assay kits and cell-based alternatives are still needed; assay formats/detection technologies that have proven useful and those most associated with assay
81
August 2012
Pub. Date 2012/06/01
Product Profiles: Asthma - Key companies act to maintain dominance

Price USD 11400 PDF by E-mail (Single user license) Published by Datamonitor
Asthma is an established and growing market dominated by key brands. However, competition is growing and generic threats are increasing, such that the market will become more fragmented. A number of pipeline products, notably once-daily ICS/LABA combinations, are expected to address unmet needs and have high clinical and commercial potential. Features and benefits
Access Datamonitor's independent clinical and commercial assessment of marketed brands and key pipeline
agents for asthma.
Understand what it takes to differentiate a product in asthma treatment and how the pipeline threatens current
market leaders.
Assess how pipeline products compare to each other and how they will compete with established therapies. Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
Pub. Date 2012/06/01
China Animal Vaccine Industry Report, 2011-2012

Price USD 2400 PDF by E-mail (Single User License) USD 2500 Hard Copy USD 3700 PDF by E-mail (Enterprise-wide License) Published by ResearchInChina
Along with the frequent outbreaks of animal epidemics, the government's increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine market shows vigorous development. In 2011, the market size of animal vaccine in China hit RMB7.92 billion. Since 2004, foot-and-mouth disease, highly pathogenic avian influenza (HPAI), highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS), swine fever and peste des petits ruminants have been brought into the scope of compulsory immunization by the government, which promotes the animal vaccine market to grow 28.1% annually. It is expected that Chinese market size of animal vaccine will amount to RMB9.56 billion in 2012. Pig and poultry raising is the backbone of Chinese animal husbandry, and the swine and poultry vaccines occupy more than 80% of China's animal vaccine market. In 2011, the total sales of animal vaccines produced by Chinese animal vaccine enterprises approximated RMB7.11 billion (excluding net import value), of which the sales of swine vaccine and poultry vaccine registered RMB3.51 billion and RMB3.01 billion respectively, making up 49.4% and 42.3% of the total sales separately. Chinese animal vaccine industry features high degree of industry concentration. In 2011, among major Chinese animal vaccine manufacturers, China Animal Husbandry Industry Co., Ltd. ranked No. 1 for its revenue of RMB1.18 billion, accounting for 14.9% market share. Moreover, the companies with market share of over 5.0% also include Xinjiang Tecon Animal Husbandry Bio-technology Co., Ltd., Guangdong Dahuanong Animal Health Products Co., Ltd. and Jinyu Group. As the state strengthens the regulatory oversight and the consumer's brand awareness is improving, the concentration degree of Chinese animal vaccine industry will be enhanced as well.
82
August 2012
Pub. Date 2012/06/01
Research Report on China's Blood Product Industry, 2012

Price USD 3000 Hard Copy USD 3000 PDF by E-mail (Single user license) USD 4500 PDF by E-mail (Enterprisewide license) Published by China Research and Intelligence
Blood products are made through separating and purifying various proteins in plasmas and they are mainly composed of four categories, the albumin, immunoglobulin, blood coagulation factors and other minorities. Chinese enterprises mainly produce nine kinds of products in the first three categories. The market concentration of global blood products is very high. Blood products of five enterprises in developed countries totally account for 80% to 85% of the market share. In 2011, the global plasma input volume was 32,799 tons and the market scale reached USD 16.3 billion, with an increase of 9.2% YOY. At present, the global blood market relatively keeps steady and emerging economies are the main growing force. The supervision on China's blood product industry is very strict; the barriers to entry are high and the import of the majority of blood products is restricted. By May, 2012, there were 23 regular blood product manufacturers in China; the plasma input volumes were not big and the market concentration was low. In 2011, the plasma input volume of China's blood product enterprises was 3,620 tons in total, with an increase of 10.3% over 2010; the market scale was CNY 11.2 billion, with a rapid increase of 22.17% YOY. Because the output of Chinese blood products is far less than the domestic demand, the competition is not intensive. According to the market research by CRI, Chinese blood products are in short supply currently. Manufacturers are generally without stocks and products are always ordered in advance. Due to the low utilization of production capacity, the majority of Chinese blood products enterprises all have no productivity expansion plans recently. In addition, because the demand exceeds the supply, the actual price of blood products in Chinese market is possibly far higher than the maximum limit price set by the government. Therefore, the margin of the industry is very high. It is expected that the Chinese government's examination and approval for plasma stations will be loosened in the future. Therefore, the market scale, plasma input volume and authorized volume will constantly increase. Moreover, the output increase will be digested by the powerful future demand. Consequently, the market competition in the future years is not fierce either.
83
August 2012
Pub. Date 2012/06/01
Chinese Markets for Pharmaceutical Packaging

Price Published by Asia Market Information & Development USD 4000 PDF by E-mail (Single User License) USD 8000 PDF by E-mail (Corporate Use License) China's demand for pharmaceutical packaging has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled. Table of Contents I. INTRODUCTION II. BUSINESS ENVIRONMENT III. PHARMACEUTICAL PACKAGING INDUSTRY ASSESSMENTS IV. PHARMACEUTICAL PACKAGING PRODUCTION AND DEMAND V. PHARMACEUTICAL PACKAGING MARKETS OUTLOOK VI. MARKETING STRATEGIES VII. PHARMACEUTICAL PACKAGING PRODUCER DIRECTORY
84
August 2012
Pub. Date 2012/06/01
Life Sciences & Analytical Reagents Market - Applications, Current Trends, Opportunities & Global Forecasts (2011 - 2016)
Price USD 4650 PDF by E-mail (Single User License) USD 5650 PDF by E-mail (Multi User License) USD 7150 PDF by E-mail (Corporate License) USD 9000 PDF by E-mail (Enterprise Site License) Published by Markets and Markets
Biotechnology (life science and analytical) reagents are the substances or compounds used to detect or synthesize another substance in order to provide a test reading. These reagents are used in the field of research, diagnosis, bioscience, and education. The life sciences and analytical reagents market report studies the life science and analytical reagents market, by technology, end-users, and applications. The life sciences and analytical reagents market, by technology studied in this report are segmented as life science reagents and analytical reagents; of which life science segment accounted for the largest share of 59.37% of the total market in 2011. The global life science and analytical reagents market was valued at $40,308.8 million in 2011 and is expected to reach $59,319.2 million by 2016; growing at a CAGR of 8% from 2011 to 2016. The life sciences and analytical reagents market is driven by the increasing use of reagents in therapeutics, basic research and commercial applications. The demand for biotechnology reagents is mainly dependent upon the growth of the biotechnology instrumentation market. The biotechnology instrumentation market continues to witness significant growth due to an increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology companies, thus augmenting the demand for biotechnology instruments. Continual product developments are being witnessed in various industries, such as pharmaceutical/bio-pharmaceutical, agri-biotech, and food and beverages; this is expected to facilitate market growth. North America dominated the life sciences and analytical reagents market with 46.28% share in 2011. Successful completion of the first phase of the Human Genome Project, ahead of schedule, has given rise in the U.S. reagent market. Investments, government funding, and new products are driving the reagents market in the U.S. The Asian market, however, shows greater opportunities, when compared to other regions, with the highest CAGR of 11.8% from 2011 to 2016; due to increased research outsourcing activities in the life technology field.
85
August 2012
Pub. Date 2012/06/01
Global Flow Cytometry Market

Price USD 3400 PDF by E-mail (Single User License) USD 6800 PDF by E-mail (Enterprise License) Published by Trimark Publications
Flow cytometry is a laboratory analytical technique that can rapidly measure multiple parameters of individual cells or particles as they pass through a beam of light, typically a laser. The global flow cytometry market remains one of the fastest-growing segments of life sciences and clinical diagnostics markets. In the current life sciences research, pharmaceutical drug discovery and development, and clinical diagnostics markets, flow cytometry offers some of the brightest promise for growth and innovation. The purpose of this TriMark Publications report is to provide a detailed analysis of the global flow cytometry market, including size, growth, technology platforms, applications, new instrumentation, industry trends and the internal structure of the sector. The study covers highly attractive growth areas such as stem cell research, biomarkers and companion diagnostics, CD4 testing, high throughput screening and immunology and vaccine development. It also analyzes almost all of the companies known to be marketing, manufacturing or developing flow cytometry products in the U.S. and worldwide. Additionally, this review provides detailed tables, charts and figures with past and projected sales data by geographic region for North America, Europe, Asia-Pacific and the emerging BRIC (Brazil, Russia, India and China) markets.
Pub. Date 2012/06/01
The New Generation of Antibody Therapeutics: Current Status and Future Prospects
Price USD 2495 PDF by E-mail (Single User License) USD 3995 PDF by E-mail ( Single Site License) USD 9950 PDF by E-mail (Multi Site License) Published by Insight Pharma Reports
Antibody sales are predicted to reach $50 billion this year. This Insight Pharma Report focuses on recent developments in the therapeutic antibody field and new technologies built on the foundations of previously successful and unsuccessful strategies. Following a review of the business environment and market forces, this report examines:
The state of the art, and the needs and direction, of antibody technology today Antibody conjugates and other payloads: construction, clinical development, and corporate activity Multispecific and multifunctional antibodies: construction, clinical development, and corporate activity Development of biosimilars and biobetters: commercial and regulatory issues Advances in product development technologies and overcoming biomanufacturing challenges IP challenges, deal structures, mergers and acquisitions Marketed and clinical pipeline products, current status and future forecast Strategies, technologies, and pipelines of selected new-generation antibody companies Future potential impact of systems biology and nanotechnology Strategic issues, economic outlook, and opportunities for future products Insights from thought leaders interviewed for this report
86
August 2012
Pub. Date 2012/06/01
DNA Sequencing and PCR Markets

Price USD 3400 PDF by E-mail (Single User License) USD 6800 PDF by E-mail (Enterprise License) Published by Trimark Publications
DNA sequencing and polymerase chain reaction (PCR) are two major technology platforms of value in life science research, drug discovery and clinical diagnostics. The markets for sequencing are extremely competitive, driven by rapid technological advancements and aggressive price wars. Next-generation sequencing presents an exciting area of growth for life science tool vendors, including those providing sequencers, ancillary instrumentation, reagents and software. This TriMark Publications report provides an in-depth analysis of key technology and market trends in the high-throughput sequencing space while analyzing the main drivers of growth in markets for PCR products and applications. The study provides a thorough overview of DNA sequencing and PCR, including applications, opportunities, technological trends, and market share and dynamics with a particular focus on the U.S, Japan, European, and Brazil, Russia, India and China (BRIC) markets. This report also analyzes almost all of the companies known to be marketing, manufacturing or developing DNA sequencing and PCR products in the U.S. and worldwide. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.
Pub. Date 2012/06/01
Transdermal Hormone Replacement: Products, Players, Markets and Forecasts

Greystone Research Associates is pleased to announce the publication of a new market study. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, device packaging designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for therapeutic hormones administered transdermally. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
87
August 2012
Pub. Date 2012/06/01
Ear Care - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the ear care category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the ear care market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our ear care market research answer questions such as:
What is the market size of ear care? What are the major brands in ear care? What are the major brands in ear care? Which products relieve swimmer's ear? Are tinnitus drops available in ear care?
88
August 2012
Pub. Date 2012/06/01
Systemic Nasal Sprays: Products, Players, Markets and Forecasts

Greystone Research Associates is pleased to announce the publication of a new market study. Systemic Nasal Sprays: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, device packaging designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for systemic drugs that are administered intranasally. Provider organization business managers, healthcare administrators and investors will also benefit from this study. The Evolving Landscape Drug developers and researchers are discovering that the accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics, systemically as well as across the blood-brain barrier to the CNS. Nasal delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patientfriendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization. Intranasal delivery will grow at the expense of the predominant drug delivery methods (oral and parenteral), which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.
Pub. Date 2012/06/01
Wound Care - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the wound treatments category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the wound treatments market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our wound treatments market research answer questions such as:
What is the market size of wound treatments? What are the major brands in wound treatments? What novel technologies are being used in sticking plasters/adhesive bandages
89
August 2012
Pub. Date 2012/06/01
Weight Management - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the slimming products category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the slimming products market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our slimming products market research answer questions such as:
What is the market size of slimming products? What are the major brands in slimming products? What are the major brands in slimming products? Do consumers prefer appetite suppressants, blockers, burners, or craving suppressants? Are slimming teas popular?
Pub. Date 2012/06/01
Nrt Smoking Cessation Aids - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the NRT smoking cessation aids category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the NRT NRT smoking cessation aids market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our NRT smoking cessation aids market research answer questions such as:
What is the market size of NRT smoking cessation aids? What are the major brands in NRT smoking cessation aids? How have tobacco bans affected the sales of NRT smoking cessation aids?
90
August 2012
Pub. Date 2012/06/01
Medicated Skin Care - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the medicated skin care category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the medicated skin care market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our medicated skin care market research answer questions such as:
What is the market size of medicated skin care? What are the major brands in medicated skin care? What are the most popular formats for acne treatments?
Pub. Date 2012/06/01
Herbal/Traditional Products - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the herbal and traditional products category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the herbal and traditional products market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our herbal and traditional products market research answer questions such as:
What is the market size of herbal and traditional products? What are the major brands in herbal and traditional products? What are the major brands in herbal and traditional products? Are ayurvedic or traditional chinese medicine products available? Which traditional products, like charcoal, bird's nest, camphor, valerian, or menthol, are popular?
91
August 2012
Pub. Date 2012/06/01
Eye Care - Country Reports

Price Please contact us for pricing Published by Euromonitor International Euromonitor has the world's most comprehensive research on the eye care category within the consumer health industry. We monitor and analyse industry trends around the world, including in-depth data on market share and market size - from the big picture qualitative analysis; down to specific category data. Euromonitor data and market analysis cultivates your organization's awareness of the eye care market and the greater competitive environment, ensuring accurate and focused strategies for your business. A resource for your entire organization, Euromonitor market research supports every level of business, assisting in strategic development, marketing, mergers and acquisitions, and brand management. Our eye care market research answer questions such as:
What is the market size of eye care? What are the major brands in eye care? How are population trends affecting eye care product sales?
Pub. Date 2012/06/01
Oral Transmucosal Drug Delivery: Products, Players, Markets & Forecasts

Greystone Research Associates is pleased to announce the publication of a new market study. Oral Transmucosal Drug Delivery: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for drug delivery films, sprays, lozenges, wafers and orally dissolvable tablets that are designed to be administered into the oral cavity and be absorbed systematically via the oral mucosa. Provider organization business managers, healthcare administrators and investors will also benefit from this study. Safety, Compliance and Oral Drug Technology In their search for alternative delivery methods that will enhance compliance and improve safety, drug developers and researchers are discovering that the permeability of mucous membranes provides a convenient route for the systemic delivery of new and existing therapeutic drugs. Transmucosal delivery offers the potential for once daily dosing of oral drugs and avoids the effects of first pass metabolism. On the provider side, the development of alternative methods of drug administration has improved the ability of physicians to manage specific problems. Practitioners now recognize the rapid onset, relative reliability, and the general lack of patient discomfort when drugs are administered by the transmucosal route. We expect this market to experience healthy growth through 2016 as absorbable solid dosage technology is applied to existing drugs and as absorbable formulations become an important route of administration for an increasing number of new NCEs. Growth in this sector will also be driven by the pressure to extend market protection for numerous existing drugs with soon-to-expire patents.
92

Pharmaceutical and Biotechnology Market Report Catalog - August 2012

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Pharmaceutical and Biotechnology Market Report Catalog - August 2012

Uploaded by

Copyright:

Available Formats

Market Report Catalog Pharmaceutical/Biotechnology

Global Information, Inc.

United States Market for Ankylosing Spondylitis Pharmacotherapy

Pub. Date 2012/07/05

United States Market for Rheumatoid Arthritis Pharmacotherapeutics

Analysis of the Therapeutic Monoclonal Antibodies Market in Europe

Pub. Date 2012/07/03

Single Cell Technologies Trends 2012

Strategic Analysis of the Clinical Research Organization Market in India

Pub. Date 2012/07/02

Global Markets for Stem Cells

Toxoplasmosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Pre-Diabetes/Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2012

Congenital Heart Disease Global Clinical Trials Review, H1, 2012

Pub. Date 2012/06/30

Open-Angle Glaucoma Global Clinical Trials Review, H1, 2012

Pub. Date 2012/06/30

Chronic Pain Global Clinical Trials Review, H1, 2012

Ulcers Global Clinical Trials Review, H1, 2012

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2012

Nonmelanomatous Skin Cancer Global Clinical Trials Review, H1, 2012

Kinase Inhibitors: Global Markets -- Focus on Europe

Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Atopic Dermatitis (Eczema) Global Clinical Trials Review, H1, 2012

Pub. Date 2012/06/30

Pregnancy Global Clinical Trials Review, H1, 2012

Kinase Inhibitors: Global Markets -- Focus on the U.S.

Pub. Date 2012/06/30

General Anxiety Disorder Global Clinical Trials Review, H1, 2012

Other Metabolic Disorders Global Clinical Trials Review, H1, 2012

Pub. Date 2012/06/30

Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

Kinase Inhibitors: Global Markets -- Focus on Asia

Pub. Date 2012/06/29

Analysis of the U.S. Cancer Biomarker Testing Market

China Blood Products Industry Report, 2011-2012

Pub. Date 2012/06/29

United States Market for Psoriatic Arthritis Pharmacotherapy

Medical Information Teams and Call Center Management

Pub. Date 2012/06/27

Global Markets for Membrane Technology for Pharmaceuticals

Healthcare Landscape, Outlook, and Growth Opportunities in Brazil

Kinase Inhibitors: Global Markets

Best Practices: The Evolving Commercial Genomics IT Landscape

Global Markets for Enzyme Inhibitors -- Focus on the US

Pub. Date 2012/06/22

World Wound Care Markets (Skin Ulcer, Burns, Surgical/Trauma)

Breast Cancer Diagnostic and Drug Technologies: Global Markets

Pub. Date 2012/06/22

Global Markets for Enzyme Inhibitors -- Focus on Europe

Global Markets for Enzyme Inhibitors -- Focus on Emerging Markets

Pub. Date 2012/06/20

ELISA Assay Trends 2012

Deglutition Disorders Global Clinical Trials Review, H1, 2012

Japan Sexually-Transmitted Diseases: Market Outlook and Emerging Opportunities

Pub. Date 2012/06/18

Healthcare, Regulatory and Reimbursement Landscape Vietnam

Varicose Veins Global Clinical Trials Review, H1, 2012

Sedation Global Clinical Trials Review, H1, 2012

Pub. Date 2012/06/18

Pub. Date 2012/06/18

Strabismus Global Clinical Trials Review, H1, 2012

Reperfusion Injury Global Clinical Trials Review, H1, 2012

Pub. Date 2012/06/18